NEW YORK (GenomeWeb) – HalioDx today announced its inception following a buyout by Qiagen Marseille's former executive management team. 

The company will focus on the immuno-oncology diagnostics space and develop assays for predicting patient response to several immuno-oncology solid tumor treatments.  

Along with Qiagen Marseille's managers, all of its 75 employees have transferred to HalioDx, a spokesperson for HalioDx told GenomeWeb. The firm's CEO is Vincent Fert.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.